Menopur

Menotrophin, the active ingredient in Menopur, is a gonadotropin presented as an injectable solution for subcutaneous use. It treats infertility caused by anovulation and is employed in assisted reproductive technologies such as in‑vitro fertilisation.

GNH USA supplies Menopur as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, fertility clinics and pharmacies worldwide.

Menopur is a gonadotropin used to stimulate ovarian function in various infertility contexts.

- Infertility due to anovulation: promotes follicular development to enable ovulation. - Assisted reproductive technology (IVF): supports controlled ovarian stimulation for egg retrieval. - Intrauterine insemination (IUI): enhances follicular growth to improve timing and success of insemination.

Menopur may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Injection site pain: mild discomfort at the injection site. - Abdominal bloating: feeling of fullness or mild distension. - Headache: occasional mild to moderate headache. - Nausea: transient feeling of queasiness.

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome: severe swelling and fluid shift. - Multiple pregnancy: increased chance of twins or higher order gestations. - Severe allergic reaction: rash, swelling, or anaphylaxis.

Menopur requires careful clinical monitoring to minimise risks.

- Monitor ovarian response: regular ultrasound and hormone checks. - Assess contraindications: avoid in patients with ovarian cysts or active malignancy. - Avoid use with uncontrolled thyroid disease: thyroid status can affect response. - Use caution in patients with a history of thromboembolism: increased clotting risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Menopur can interact with other hormonal agents and medications affecting coagulation.

Major Interactions (Avoid): - Estrogen‑containing contraceptives: may reduce gonadotropin efficacy. - Concurrent use of other gonadotropins: heightens risk of ovarian hyperstimulation. - Anticoagulants: may increase bleeding at injection sites.

Moderate Interactions (Monitor Closely): - Corticosteroids: can alter ovarian response. - Thyroid hormone therapy: may affect stimulation outcomes. - Antipsychotics that raise prolactin: could modify treatment effectiveness.